ArticleBMC oral health2025
Retrospective analysis of peri-implant tissue health and patient reported outcome measures in indirect sinus floor augmentation in diabetic and non-diabetic patients.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImplant therapy is a predictable solution for replacing missing teeth; however, the posterior maxilla presents challenges due to limited residual bone height and porous bone quality. The primary outcome of this retrospective study was to compare peri-implant tissue health—specifically total bone height (TBH) and marginal bone loss (MBL)—between well-controlled type 2 diabetes mellitus (T2DM) and non-diabetic patients over a 10-year period. Patient-reported outcome measures (PROMs) were evaluated as a secondary outcome.
methodsSeventy-six patients received 115 implants placed in the posterior maxilla with indirect sinus floor elevation. Based on metabolic status, patients were categorized into well-controlled T2DM (n = 31) and non-diabetic groups (n = 45). Clinical and radiographic parameters—gingival index (GI), residual bone height (RBH), sinus membrane elevation (SME), total bone height (TBH), marginal bone loss (MBL), sinus membrane thickness (SMT), and peri-implant soft tissue dehiscence (PSTD)—were assessed at baseline to 10 years follow up. PROMs were assessed using the OHIP-14 scale.
resultsAt 10-year follow-up, the mean total bone height was 14.05 ± 1.03 mm in the T2DM group and 14.65 ± 0.99 mm in the non-T2DM group, reflecting a mean difference of 0.60 mm (P = 0.002). Mean marginal bone loss was 1.21 ± 0.72 mm in T2DM patients vs. 0.56 ± 0.61 mm in non-diabetic patients, with a mean difference of 0.65 mm (P < 0.001). PROMs indicated similar patient satisfaction between groups, although esthetic and functional scores declined more in T2DM patients over time.
conclusionBoth groups showed comparable long-term clinical outcomes, though lesser total bone height and greater mean marginal bone loss was observed in diabetic patients. Indirect sinus floor elevation with composite grafting demonstrated predictable success in both well-controlled T2DM and non-T2DM patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.